PMH18 Incidence of antipsychotic polypharmacy in the texas medicaid population  by Desai, P et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A211
the fully adjusted HR was 2.03; 95% CI (1.13-3.65) among children exposed to SSRIs 
alone and 4.10; 95% CI (1.35-12.41) among children exposed to combined classes 
of antidepressant. ConClusions: This study suggests that use of antidepressant 
during the 2nd/3rd trimester of pregnancy may increase the risk of ASD.
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objeCtives: To estimate the incidence of antipsychotic polypharmacy (APP) in 
the Texas Medicaid population. Methods: Adults newly initiated on antipsychot-
ics between July 1, 2006 and December 31, 2010 were followed for 365 days after 
the index antipsychotic claim. APP was defined as the concomitant use of two or 
more antipsychotics for at least 60 days without a gap in polypharmacy greater 
than 31 days. Monotherapy (MT) was defined as exposure to no more than one 
antipsychotic at a time during the one year after the index antipsychotic claim. 
Sensitivity analyses were conducted to determine how variations in the definition of 
APP impacted incidence. Results: Of the 23,232 patients meeting eligibility criteria, 
5.4% (N= 1,253) were on APP and 94.6% (N= 21,979) on MT during the study period. 
Among those on APP, 70.1% used a combination of atypicals, 1.1% used a combina-
tion of typicals, 27.7% used a combination of a typical and an atypical, 0.8% used 
clozapine and an atypical, and 0.3% used clozapine and a typical. Among those on 
MT, 7% used typicals, 92.9% used atypicals, and 0.2% used clozapine. Patients with 
APP had a mean of 106.6±94.2 (median= 86, interquartile range [IQR]= 168) days prior 
to starting polypharmacy, a mean of 141.4±77.7 (median= 118, IQR= 108) days on poly-
pharmacy, and a mean of 1.1±0.3 (median= 1, IQR= 0) APP episodes per patient. When 
the overlap period for antipsychotics was increased from 60 to 120 and 180 days, the 
incidence of APP fell from 5.4% to 2.2% and 1.3%, respectively. When the gap period 
was varied from 31 to 15 and 45 days, the incidence of APP changed from 5.4% to 
4.6% and 6.9%, respectively. ConClusions: Although no clinical guidelines support 
APP, it was still seen for some patients in the study population. Future studies should 
be conducted to evaluate the costs and outcomes associated with this practice.
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objeCtives: Depression is one of the most common disorders among the elderly 
nursing home residents. However, little is known about the demographic and 
behavioral characteristics of elderly nursing home residents with depression in the 
United States. Methods: A cross-sectional study was conducted using 2007-2008 
Minimum Data Set (MDS) linked to Medicare enrollment file to identify residents 
65 years or older with depression. Patients with full coverage for Medicare Parts 
A, B and D for the entire study period or until the date of death were included in 
the study. Descriptive statistics was performed to determine socio-demographic 
and behavioral characteristics of elderly nursing home residents with depres-
sion. Results: The national study cohort consisted of 833,453 elderly nursing home 
residents with depression. Mean age of the residents was 81.09 ± 8.23 years. Most 
of the patients were females (78.26%), Whites (85.36%), widowed (49.66%) and had 
high school education (26.22%). The majority of the residents were diagnosed with 
hypertension (88.37%), followed by anemia (70.01%), dementia (65.74%), ischemic 
heart disease (61.34%), rheumatoid arthritis (58.86%) and congestive heart failure 
(55.22%). Antidepressants (68.09%) were the most commonly used drug class fol-
lowed by diuretics (39.22%) and antipsychotics (24.79%). Among the residents with 
assessments, the mean Index of Social Engagement score (range 0-6) was 2.43 ± 
1.57. The mean Depression Rating Scale score (range 0-14) was 0.99 ± 1.59. The 
mean Aggressive Behavior Scale score (range 0-12) was 0.51 ± 1.27 in the study 
sample. ConClusions: Elderly nursing home residents with depression suffer 
from significant comorbidities. Most of these residents are managed by antide-
pressant pharmacotherapy. Further research is needed to address evidence gap 
regarding the safety and effectiveness of many medications used by the elderly 
nursing home residents.
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objeCtives: Anticholinergic medication use in elderly dementia patients is of great 
concern due to cognitive and central side-effects associated with these agents. 
Consequently, anticholinergic medications are considered inappropriate in elderly 
dementia patients. This study examined the prevalence and predictors of inappro-
priate anticholinergic medication use in elderly dementia patients using multi-year 
national survey data. Methods: The study involved a retrospective cross-sectional 
study design using 2009-2010 Medical Expenditure Panel Survey (MEPS). The study 
sample included patients aged ≥ 65 years diagnosed with dementia. Inappropriate 
anticholinergic medications were identified using the revised American Geriatrics 
Society (AGS) Beers’ criteria. Descriptive statistics using sampling weights were 
used to estimate the prevalence of inappropriate anticholinergic medication use. 
Multivariable logistic regression within the conceptual framework of Anderson 
Behavioral Model was used to identify the factors associated with inappropriate 
anticholinergic use in elderly dementia patients. Results: According to the MEPS, 
a total of 3.78 million (95% CI: 3.17-4.38) elderly patients had dementia for an overall 
prevalence of 4.81%. An estimated 1.02 million dementia patients (95% CI: 0.70-
1.3) reported use of inappropriate anticholinergic medications for a prevalence 
PMH15
rIsk of HyPonatreMIa aMong tHe IncIdent users of antIdePressants
Shewale A.R., Shah A., Painter J.
University of Arkansas for Medical Sciences, Little Rock, AR, USA
objeCtives: Newer antidepressants selective serotonin reuptake inhibitors (SSRIs) 
and serotonin norepinephrine reuptake inhibitors (SNRIs) are the most commonly 
prescribed antidepressants. This is due mostly to their better side effect profile 
when compared to older drugs like tricyclic antidepressants (TCAs). However 
these classes are not completely bereft of side effects. Hyponatremia is a condition 
in which the serum sodium level falls below normal; it has been proposed this 
occurrence is associated with the binding affinity to the 5-HT receptor. The objec-
tive of our study is to compare the incidence of hyponatremia among the newer 
classes of antidepressants. Methods: We used a cohort study design using Lifelink 
claims data to compare the incidence of hyponatremia in TCAs, SSRIs, and SNRIs. 
Incidence was reported per 10,000 person-years. Cox model was used to assess 
the risk of adverse events while adjusting for potential confounders. Results: 
A total of 314,796 patients with an incident prescription for a TCA, SSRI, or SNRIs 
were identified and met study inclusion criteria. The unadjusted hazard ratio for 
hyponatremia in patients on SSRIs was 0.789 (C.I= 0.729-0.854) and on SNRIs was 
1.112 (C.I= 0.976-1.268) when compared to TCAs. However, after adjusting for covari-
ates using the Cox model the hazard ratios were found to be 1.013 (C.I= 0.934-1.099) 
for SSRIs and 1.069 (C.I= 0.937-1.221) for SNRIs again compared to TCAs. After doing 
stepwise regression to remove covariates that did not have significant effect the 
results remained similar, 1.017(C.I= 0.939-1.101) for SSRIs and 1.074 (C.I= 0.941-1.225) 
for SNRIs. ConClusions: No significant increase in the risk of hyponatremia for 
SSRIs or SNRIs over TCAs was found. The covariates we identified show significant 
interaction with hyponatremia. However, the results must be interpreted with cau-
tion as the ICD-9 code that identifies hyponatremia has been shown to have a sen-
sitivity below 30%, thus our analysis potentially excludes a large number of cases.
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objeCtives: Anticholinergic medications are extensively used in nursing homes. 
However, limited data exists regarding the utilization pattern of anticholinergic 
medications among residents with depression. The current study evaluated the 
extent of anticholinergic medication use in elderly nursing home residents with 
depression. Methods: A retrospective cross-sectional study was conducted using 
2007-2008 Medicare data from all US states. The study sample consisted of nurs-
ing home residents aged 65 years or older, who had depression. Patients with full 
coverage for Medicare Parts A, B and D and no HMO coverage for the entire study 
period or until the date of death were included in the study cohort. Anticholinergic 
medications were identified using the Anticholinergic Drug Scale (ADS), which 
classifies drugs into four categories based on their level of anticholinergic activ-
ity. Descriptive statistics was performed to determine the prevalence patterns of 
anticholinergic medication use in elderly residents with depression. Results: 
The study included 833,453 elderly residents with depression; of them, 798,880 
used anticholinergic medications for an overall prevalence of 95.85%. The highest 
prevalence was seen for level 1 anticholinergics (92.83%), followed by level 3 (45.63%) 
and level 2 drugs (27.24%). Nearly 62% of the residents used medications with sig-
nificant anticholinergic properties (level 2 or 3). Among the level 2 anticholinergics, 
the most commonly prescribed medications were quetiapine (12.68%), paroxetine 
(8.38%), cyclobenzaprine (4.49%), solifenacin (2.55%) and darifenacin (2.14%). The 
most frequently prescribed level 3 anticholinergics were promethazine (13.08%), 
tolterodine (8.06%), oxybutynin (6.95%), olanzapine (6.67%), hydroxyzine (6.24%), 
meclizine (5.86%) and amitriptyline (3.86%). ConClusions: The study found that, 
over 6 in10 elderly nursing home residents with depression used medications with 
significant anticholinergic properties. In light of significant central and peripheral 
adverse effects of these agents, there is a need to optimize the use of anticholinergic 
medications among the elderly residents with depression.
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objeCtives: To our knowledge, four studies have attempted to investigate the asso-
ciation between gestational maternal use of antidepressant and risk of Autism 
Spectrum Disorder (ASD). However, several methodological drawbacks remain in 
these studies. We sought to assess the impact of gestational antidepressant use 
on the risk of (ASD) in children, controlling adequately for potential confounding 
factors. Methods: A large population-based cohort study including all singletons 
at term live births during 1998-2009 was conducted using data from the Quebec 
Pregnancy Cohort. Antidepressant exposure during pregnancy was defined accord-
ing to trimester of use and specific classes. Events were infants having diagnosis of 
ASD before December 31st, 2009. We used a survival analysis to estimate crude and 
adjusted hazards ratio (HRs) with 95% confidence intervals by means Cox propor-
tional hazards regression. Results: of 145 456 children born from 1998 through 
2009, 1 045 (0.67%) were identified with ASD. The mean age of the children at the 
end of follow up was 6.24 ±3.19 (median, 7.00). We identified 4 724 (3.24%) children 
exposed to antidepressant during overall pregnancy and 9 207 (6.32%) children 
exposed one year prior pregnancy. Among 4 724 children exposed to antidepres-
sant during pregnancy, 4 200 (2.88%) were exposed during first trimester and 2 532 
(1.74%) were exposed during 2nd/3rd trimester. We found only exposure to any anti-
depressant during 2nd/3rd trimester was associated with significantly increased risk 
of ASD (aHR= 1.81; 95% CI (1.12-2.93)). When compared the risk of ASD for different 
classes of antidepressant use during 2nd/3rdwith unexposed to any antidepressant, 
